165 related articles for article (PubMed ID: 17907501)
21. Emergence of therapy-unrelated CML on a background of BCR-ABL-negative JAK2V617F-positive chronic idiopathic myelofibrosis.
Jallades L; Hayette S; Tigaud I; Johnston A; Coiffier B; Magaud JP; Ffrench M
Leuk Res; 2008 Oct; 32(10):1608-10. PubMed ID: 18448166
[TBL] [Abstract][Full Text] [Related]
22. The role of cytology, cytochemistry, immunophenotyping and cytogenetic analysis in the diagnosis of haematological neoplasms. General Haematology Task Force of the BCSH.
Clin Lab Haematol; 1996 Dec; 18(4):231-6. PubMed ID: 9054693
[TBL] [Abstract][Full Text] [Related]
23. [New molecular markers within the chronic myeloproliferative disorders. II: the JAK2 mutation].
Larsen TS; Pallisgaard N; Christensen JH; Gram-Hansen P; Kerndrup GB; Møller MB; Hasselbalch HC
Ugeskr Laeger; 2006 Sep; 168(39):3299-303. PubMed ID: 17032592
[TBL] [Abstract][Full Text] [Related]
24. Molecular methods in diagnosis and monitoring of haematological malignancies.
Yeung DT; Parker WT; Branford S
Pathology; 2011 Oct; 43(6):566-79. PubMed ID: 21881536
[TBL] [Abstract][Full Text] [Related]
25. Proposals for standardized protocols for cytogenetic analyses of acute leukemias, chronic lymphocytic leukemia, chronic myeloid leukemia, chronic myeloproliferative disorders, and myelodysplastic syndromes.
Haferlach C; Rieder H; Lillington DM; Dastugue N; Hagemeijer A; Harbott J; Stilgenbauer S; Knuutila S; Johansson B; Fonatsch C
Genes Chromosomes Cancer; 2007 May; 46(5):494-9. PubMed ID: 17311250
[TBL] [Abstract][Full Text] [Related]
26. Atypical chronic myeloid leukemias.
Oscier D
Pathol Biol (Paris); 1997 Sep; 45(7):587-93. PubMed ID: 9404484
[TBL] [Abstract][Full Text] [Related]
27. Infrequent hypermethylation of WIF-1 promoter in BCR/ABL-negative myeloproliferative disorders.
Suzuki R; Onizuka M; Kojima M; Shimada M; Tsuboi K; Ogawa Y; Kawada H; Ando K
Tokai J Exp Clin Med; 2007 Dec; 32(4):131-5. PubMed ID: 21318952
[TBL] [Abstract][Full Text] [Related]
28. Development of chronic myeloid leukemia in a patient previously diagnosed with a JAK2-positive myeloproliferative neoplasm.
De Bruyne S; Steel E; Petrick M; Denys B; Vandepoele K; Van Roy N; Degandt S; Ghys T; Louagie H
Clin Chem Lab Med; 2021 Sep; 59(10):e392-e394. PubMed ID: 33964201
[No Abstract] [Full Text] [Related]
29. Kinase drug discovery approaches in chronic myeloproliferative disorders.
Kumar C; Purandare AV; Lee FY; Lorenzi MV
Oncogene; 2009 Jun; 28(24):2305-13. PubMed ID: 19421140
[TBL] [Abstract][Full Text] [Related]
30. A thrombocytosis occurring in Philadelphia positive CML in molecular response to imatinib can reveal an underlying JAK2(V617F) myeloproliferative neoplasm.
Véronèse L; Tchirkov A; Richard-Pebrel C; Ledoux-Pilon A; Fleury J; Chaleteix C; Goumy C; Gouas L; Berger MG; Vago P; Bay JO; Tournilhac O
Leuk Res; 2010 Apr; 34(4):e94-6. PubMed ID: 19833389
[No Abstract] [Full Text] [Related]
31. JAK2-V617F mutation in Moroccan patients with myeloproliferative disorders: contribution, diagnosis and therapeutic prospects.
Benmoussa A; Dehbi H; Fehri S; Quessar A; Nadifi S
Pathol Biol (Paris); 2011 Aug; 59(4):e89-92. PubMed ID: 19939582
[TBL] [Abstract][Full Text] [Related]
32. Idiopathic hypereosinophilic syndrome and "eosinophilic leukemia".
Cassi E; De Paoli A; Fava S; Luoni M; Tosi A; Turri C; Grimi E
Haematologica; 1992; 77(5):430-2. PubMed ID: 1483595
[TBL] [Abstract][Full Text] [Related]
33. [Optimising therapy in patients with haematological malignancies].
Dumontet C
Bull Cancer; 2008 Oct; 95(10):959-62. PubMed ID: 19004726
[TBL] [Abstract][Full Text] [Related]
34. Myelodysplastic and myeloproliferative disorders in children.
Hasle H
Curr Opin Pediatr; 2007 Feb; 19(1):1-8. PubMed ID: 17224655
[TBL] [Abstract][Full Text] [Related]
35. Molecular cytogenetic aspects of hematological malignancies: clinical implications.
Chen Z; Sandberg AA
Am J Med Genet; 2002 Oct; 115(3):130-41. PubMed ID: 12407693
[TBL] [Abstract][Full Text] [Related]
36. Molecular diagnosis of myeloproliferative neoplasms.
Patnaik MM; Tefferi A
Expert Rev Mol Diagn; 2009 Jul; 9(5):481-92. PubMed ID: 19580432
[TBL] [Abstract][Full Text] [Related]
37. [The usefulness of the bcr/abl rearrangement in the diagnosis and evolution of chronic myeloid leukemia].
González FA; Villegas A; Ferro MT; San Román C; Sáez I; López M; del Potro E; Alvarez A; Martínez R; Díaz Madiavilla J
Med Clin (Barc); 1993 Oct; 101(14):521-4. PubMed ID: 8231395
[TBL] [Abstract][Full Text] [Related]
38. [Myelocytosis in adults. Diagnostic orientation].
Bernard P
Rev Prat; 1995 Jun; 45(11):1413-6. PubMed ID: 7659993
[No Abstract] [Full Text] [Related]
39. Beyond chronic myelogenous leukemia: potential role for imatinib in Philadelphia-negative myeloproliferative disorders.
Cortes J; Kantarjian H
Cancer; 2004 May; 100(10):2064-78. PubMed ID: 15139047
[TBL] [Abstract][Full Text] [Related]
40. The saga of JAK2 mutations and translocations in hematologic disorders: pathogenesis, diagnostic and therapeutic prospects, and revised World Health Organization diagnostic criteria for myeloproliferative neoplasms.
Smith CA; Fan G
Hum Pathol; 2008 Jun; 39(6):795-810. PubMed ID: 18538168
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
